2021
Clinical outcomes of first line FOLFIRINOX vs . gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer at the Yale Smilow Hospital System
Patel T, Miccio J, Cecchini M, Srikumar T, Stein S, Kortmanksy J, Johung K, Lacy J. Clinical outcomes of first line FOLFIRINOX vs . gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer at the Yale Smilow Hospital System. Journal Of Gastrointestinal Oncology 2021, 0: 0-0. PMID: 35070386, PMCID: PMC8748034, DOI: 10.21037/jgo-21-202.Peer-Reviewed Original ResearchMetastatic pancreatic cancerFirst-line FOLFIRINOXTreatment discontinuationFFX groupDose modificationOverall survivalNab-paclitaxelPancreatic cancerGN groupComparative effectivenessMedian TTDFirst-line settingMedian overall survivalOutcomes of patientsTreatment-related toxicityFirst-line therapyKaplan-Meier methodRate of hospitalizationElectronic medical record systemAdjuvant gemcitabineChemotherapy toxicityDiscontinuation ratesLine therapyMedical record systemTreatment toxicity
2020
The Utility of Neoadjuvant Radiotherapy after Neoadjuvant Multiagent Chemotherapy in Patients with Localized Pancreatic Cancer
Miccio J, Talcott W, Patel T, Park H, Cecchini M, Salem R, Stein S, Kortmansky J, Lacy J, Johung K, Jethwa K. The Utility of Neoadjuvant Radiotherapy after Neoadjuvant Multiagent Chemotherapy in Patients with Localized Pancreatic Cancer. International Journal Of Radiation Oncology • Biology • Physics 2020, 108: e31-e32. DOI: 10.1016/j.ijrobp.2020.02.538.Peer-Reviewed Original ResearchNeoadjuvant folfirinox in patients with (borderline) resectable pancreatic cancer: A systematic review and patient-level meta-analysis
Buettner S, Janssen Q, Suker M, Beumer B, Addeo P, Bachellier P, Bahary N, Bekaii-Saab T, Bali M, Besselink M, Boone B, Chau I, Clarke S, Dillhoff M, El-Rayes B, Frakes J, Grose D, Hosein P, Jamieson N, Javed A, Khan K, Kim K, Kim S, Kim S, Ko A, Lacy J, Margonis G, McCarter M, McKay C, Mellon E, Moorcraft S. Neoadjuvant folfirinox in patients with (borderline) resectable pancreatic cancer: A systematic review and patient-level meta-analysis. Hepato Pancreato Biliary 2020, 22: s327. DOI: 10.1016/j.hpb.2020.04.310.Peer-Reviewed Original Research
2018
Neoadjuvant FOLFIRINOX in patients with (borderline) resectable pancreatic cancer: A systematic review and patient-level meta-analysis.
Janssen Q, Buettner S, Suker M, Margonis G, Paniccia A, El-Rayes B, Bahary N, Chau I, Hosein P, Ko A, Lacy J, Jamieson N, Tinchon C, Kim K, Besselink M, Wilmink J, Homs M, van Eijck C, Katz M, Groot Koerkamp B. Neoadjuvant FOLFIRINOX in patients with (borderline) resectable pancreatic cancer: A systematic review and patient-level meta-analysis. Journal Of Clinical Oncology 2018, 36: e16207-e16207. DOI: 10.1200/jco.2018.36.15_suppl.e16207.Peer-Reviewed Original ResearchMORPHEUS: A phase Ib/II trial platform evaluating the safety and efficacy of multiple cancer immunotherapy (CIT) combinations in patients (pts) with gastric or pancreatic cancer.
Oh D, Al-Batran S, Chung H, Hollebecque A, Iqbal S, Kim K, Lacy J, Manji G, O'Reilly E, Rahma O, Yoon H, Kwan A, He X, Barak H, Sayyed P, Zhang X, Wang J, Cha E, Bekaii-Saab T. MORPHEUS: A phase Ib/II trial platform evaluating the safety and efficacy of multiple cancer immunotherapy (CIT) combinations in patients (pts) with gastric or pancreatic cancer. Journal Of Clinical Oncology 2018, 36: tps4134-tps4134. DOI: 10.1200/jco.2018.36.15_suppl.tps4134.Peer-Reviewed Original Research
2017
730P Interim health related quality of life (QoL) from LAPACT, a Phase 2 trial of nab-paclitaxel (nab-P) plus gemcitabine (G) for patients (Pts) with locally advanced pancreatic cancer (LAPC)
Portales F, Philip P, Hammel P, Buscaglia M, Pazo-Cid R, Mozo J, Kim E, Dowden S, Zakari A, Borg C, Terrebonne E, Herrero F, Li J, Ong T, Nydam T, Lacy J. 730P Interim health related quality of life (QoL) from LAPACT, a Phase 2 trial of nab-paclitaxel (nab-P) plus gemcitabine (G) for patients (Pts) with locally advanced pancreatic cancer (LAPC). Annals Of Oncology 2017, 28: v248-v249. DOI: 10.1093/annonc/mdx369.114.Peer-Reviewed Original Research622PD nab-Paclitaxel (nab-P) plus gemcitabine (G) for patients (Pts) with locally advanced pancreatic cancer (LAPC): Interim efficacy and safety results from the Phase 2 LAPACT Trial
Philip P, Lacy J, Portales F, Sobrero A, Pazo-Cid R, Mozo J, Kim E, Dowden S, Zakari A, Borg C, Terrebonne E, Herrero F, Li J, Ong T, Nydam T, Hammel P. 622PD nab-Paclitaxel (nab-P) plus gemcitabine (G) for patients (Pts) with locally advanced pancreatic cancer (LAPC): Interim efficacy and safety results from the Phase 2 LAPACT Trial. Annals Of Oncology 2017, 28: v212. DOI: 10.1093/annonc/mdx369.006.Peer-Reviewed Original Research
2015
Final analysis of a phase II study of Yale-modified FOLFIRINOX (mFOLFIRINOX) in metastatic pancreatic cancer (MPC).
James E, Cong X, Yao X, Hahn C, Kaley K, Li J, Kortmansky J, Fischbach N, Cha C, Salem R, Stein S, Hochster H, Lacy J. Final analysis of a phase II study of Yale-modified FOLFIRINOX (mFOLFIRINOX) in metastatic pancreatic cancer (MPC). Journal Of Clinical Oncology 2015, 33: 395-395. DOI: 10.1200/jco.2015.33.3_suppl.395.Peer-Reviewed Original ResearchMetastatic pancreatic cancerResponse rateProphylactic pegfilgrastimEntire cohortPhase II open-label studyFinal analysisECOG PS 0ECOG PS 0/1Grade 3/4 toxicitiesOpen-label studyPhase II studyBolus 5FUPS 0/1Febrile neutropeniaLAPC patientsPeritoneal diseaseII studyPS 0Surgical resectionUnacceptable toxicityImproved tolerabilityPeripheral neuropathyMetastatic sitesPancreatic cancerFOLFIRINOX
2014
Interim analysis of a phase II study of dose-modified FOLFIRINOX (mFOLFIRINOX) in locally advanced (LAPC) and metastatic pancreatic cancer (MPC).
James E, Yao X, Cong X, Li J, Hahn C, Kaley K, Kortmansky J, Fischbach N, Chang B, Salem R, Cha C, Stein S, Hochster H, Lacy J. Interim analysis of a phase II study of dose-modified FOLFIRINOX (mFOLFIRINOX) in locally advanced (LAPC) and metastatic pancreatic cancer (MPC). Journal Of Clinical Oncology 2014, 32: e15226-e15226. DOI: 10.1200/jco.2014.32.15_suppl.e15226.Peer-Reviewed Original ResearchMeasurement of circulating tumor DNA as a cancer biomarker in gastrointestinal malignancies using a novel next-generation sequencing method.
James E, Narayan A, Stein S, Lacy J, Patel A, Hochster H. Measurement of circulating tumor DNA as a cancer biomarker in gastrointestinal malignancies using a novel next-generation sequencing method. Journal Of Clinical Oncology 2014, 32: 217-217. DOI: 10.1200/jco.2014.32.3_suppl.217.Peer-Reviewed Original ResearchGastrointestinal malignanciesMultiple time pointsTumor DNAAdvanced pancreatic cancerTime pointsCohort of patientsTumor DNA levelsChemo-radiation therapyMetastatic colon cancerAdjuvant settingCancer biomarkersMutant ctDNABevacizumab therapyTumor mutation profilesLiver metastasesGI tumorsGI cancersPancreatic cancerUltra-deep sequencingKRAS mutationsKRAS G12D mutationColon cancerAdditional longitudinal dataInformed consentLiquid biopsySecond-line gemcitabine plus nab-paclitaxel (G+A) for advanced pancreatic cancer (APC) after first-line FOLFIRINOX: Single institution retrospective review of efficacy and toxicity.
Zhang Y, Hochster H, Stein S, Lacy J. Second-line gemcitabine plus nab-paclitaxel (G+A) for advanced pancreatic cancer (APC) after first-line FOLFIRINOX: Single institution retrospective review of efficacy and toxicity. Journal Of Clinical Oncology 2014, 32: 344-344. DOI: 10.1200/jco.2014.32.3_suppl.344.Peer-Reviewed Original ResearchAdvanced pancreatic cancerTreatment failureOverall survivalRetrospective reviewDose reductionActive first-line regimenSingle-institution retrospective reviewFirst-line FOLFIRINOXInitial dose reductionSecond-line gemcitabineYale Cancer CenterFirst-line regimenSingle institution experienceDose densityFurther dose reductionPaucity of dataECOG PSHematologic toxicityLine regimenNab-paclitaxelUnacceptable toxicityInstitution experienceCA 19Cancer CenterPancreatic cancerInterim analysis of a phase II study of dose-modified FOLFIRINOX (mFOLFIRINOX) in locally advanced (LAPC) and metastatic pancreatic cancer (MPC).
James E, Yao X, Cong X, Stein S, Kaley K, Hahn C, Cha C, Salem R, Hochster H, Lacy J. Interim analysis of a phase II study of dose-modified FOLFIRINOX (mFOLFIRINOX) in locally advanced (LAPC) and metastatic pancreatic cancer (MPC). Journal Of Clinical Oncology 2014, 32: 256-256. DOI: 10.1200/jco.2014.32.3_suppl.256.Peer-Reviewed Original ResearchMetastatic pancreatic cancerAdvanced pancreatic cancerPancreatic cancerFebrile neutropeniaResponse rateEvaluable ptsProphylactic pegfilgrastimInterim analysisPhase II open-label studyGrade 3/4 toxicitiesOpen-label studyPhase II studyFDG-PET scansSimilar response ratesECOG PSNeoadjuvant FOLFIRINOXUnderwent resectionII studySurgical resectionUnacceptable toxicityPET responseFOLFIRINOXRetrospective analysisDose reductionLabel study
2012
Single institution experience with FOLFIRINOX in advanced pancreatic cancer (PC).
Gunturu K, Thumar J, Hochster H, Stein S, Yao X, Cong X, Lacy J. Single institution experience with FOLFIRINOX in advanced pancreatic cancer (PC). Journal Of Clinical Oncology 2012, 30: e14534-e14534. DOI: 10.1200/jco.2012.30.15_suppl.e14534.Peer-Reviewed Original ResearchAdvanced pancreatic cancerMetastatic pancreatic cancerPancreatic cancerOverall survivalMetastatic PCProphylactic pegfilgrastimAdvanced unresectable pancreatic cancerECOG PS 0/1Efficacy of FOLFIRINOXGrade 3/4 fatigueUnresectable pancreatic cancerYale Cancer CenterSingle institution experienceKaplan-Meier methodWarrants further evaluationDose attenuationChemotherapy 5PS 0/1Free survivalSurgical resectionUnacceptable toxicityImproved tolerabilityPhysician's discretionRetrospective reviewInstitution experienceSingle-institution experience with FOLFIRINOX in advanced pancreatic cancer (PC).
Gunturu K, Thumar J, Hochster H, Stein S, Yao X, Cong X, Hahn C, Kaley K, Lacy J. Single-institution experience with FOLFIRINOX in advanced pancreatic cancer (PC). Journal Of Clinical Oncology 2012, 30: 330-330. DOI: 10.1200/jco.2012.30.4_suppl.330.Peer-Reviewed Original ResearchAdvanced pancreatic cancerPancreatic cancerProphylactic pegfilgrastimMetastatic PCFull dosesAdvanced unresectable pancreatic cancerECOG PS 0Efficacy of FOLFIRINOXRelative dose intensityUnresectable pancreatic cancerYale Cancer CenterMetastatic pancreatic cancerSingle institution experienceWarrants further evaluationCycle 1Age 60 yrEquivalent response ratesDose attenuationChemotherapy 5Evaluable ptsFebrile neutropeniaUnderwent resectionDose intensitySurgical resectionUnacceptable toxicity